VCG
TAK icon

Vantage Consulting Group’s Takeda Pharmaceutical TAK Stock Holding History

Vantage Consulting Group’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-225
Closed -$4K – 1397
2020
Q4 		$4K Buy
+225
New +$3.95K ﹤0.01% 1518

Other funds holding TAK

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vantage Consulting Group's TAK Position: Q1 2021 in Review

Vantage Consulting Group sold out of Takeda Pharmaceutical (TAK) in Q1 2021, closing a stake of 225 shares — an estimated $4K sold.

Vantage Consulting Group first reported a position in TAK in Q4 2020 and held it in 1 quarter. The position peaked at $4K in Q4 2020. 316 funds tracked by Wall St. Rank hold TAK as of Q1 2021.

  • Vantage Consulting Group reported no remaining Takeda Pharmaceutical position as of Q1 2021 after selling out during the quarter.
  • Vantage Consulting Group sold 225 Takeda Pharmaceutical shares in Q1 2021, an estimated $4K.
  • Vantage Consulting Group first reported a position in Takeda Pharmaceutical in Q4 2020 and held it in 1 quarter.
  • Vantage Consulting Group's Takeda Pharmaceutical position peaked at $4K in Q4 2020.
  • 316 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.